{"id":"fluoro-l-thymidine-18f","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL3400972","moleculeType":"Small molecule","molecularWeight":"214.18"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This radiopharmaceutical is a thymidine analog incorporating the positron-emitting isotope fluorine-18, allowing non-invasive visualization of tumor burden and proliferative activity via positron emission tomography (PET). The compound is taken up preferentially by cells with high DNA synthesis rates, making it useful for oncologic imaging and monitoring treatment response.","oneSentence":"Fluoro-L-thymidine-(18F) is a fluorine-18 labeled nucleoside analog that accumulates in rapidly dividing cells, enabling PET imaging of cellular proliferation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:12:54.008Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"PET imaging of tumor proliferation in various cancers"},{"name":"Assessment of treatment response in oncology"}]},"trialDetails":[{"nctId":"NCT01207895","phase":"PHASE1","title":"Molecular Determinants Affecting Fluoro-L-thymidine (FLT) Positron Emission Tomography (PET) in Rectal Cancer","status":"COMPLETED","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2010-03","conditions":"Rectal Cancer","enrollment":5},{"nctId":"NCT02241668","phase":"NA","title":"Fluoro-L-Thymidine Positron Emission Tomography (FLT PET) vs. Adv. Magnetic Resonance (MR) Techniques in Recurrent Glioma","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-06","conditions":"Brain Tumor","enrollment":""},{"nctId":"NCT02069418","phase":"PHASE2","title":"Theranostic Tool During Erlotinib Treatment in Non-small Cell Lung Cancer Patient","status":"UNKNOWN","sponsor":"University Hospital, Angers","startDate":"2014-02","conditions":"Non-small Cell Lung Cancer Metastatic or Non-small Cell Lung Cancer Recurrent, No EGFR Activating Mutation","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":27,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Fluoro-L-thymidine-(18F)","genericName":"Fluoro-L-thymidine-(18F)","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fluoro-L-thymidine-(18F), also known as 3'-Deoxy-3'-18f-Fluorothymidine, is a radiopharmaceutical used in PET scans to study various types of cancer, including brain tumors, non-small cell lung cancer, and rectal cancer. It is used to assess the accuracy of imaging techniques in determining the extent of cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}